The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Metabolites · 31.05.2024 · 14 (6) · 317
DOI: 10.3390/metabo14060317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 31.05.2024. Verfasst von Qiqiang Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by persistent respiratory symptoms and airflow limitation. While there are some available treatment options, the effectiveness of treatment varies depending on individual differences and the phenotypes of the disease. Therefore, exploring or identifying potential therapeutic targets for COPD is urgently needed. In recent years, there has been growing evidence showing that lysophospholipids, namely lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), can play a significant role in the pathogenesis of COPD. Exploring the metabolism of lysophospholipids holds promise for understanding the underlying mechanism of COPD development and developing novel strategies for COPD treatment. This review primarily concentrates on the involvement and signaling pathways of LPC and LPA in the development and progression of COPD. Furthermore, we reviewed their associations with clinical manifestations, phenotypes, and prognosis within the COPD context and discussed the potential of the pivotal signaling molecules as viable therapeutic targets for COPD treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
- Research Center for Chronic Airway Diseases, Peking University Health Science Center, Beijing 100191, China.
ORCID-Profile: Ying Liang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Q., Chen, Y., Liang, Y., & Sun, Y. (2024). The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Metabolites, 14(6), 317. https://doi.org/10.3390/metabo14060317
Vancouver
Zhou Q, Chen Y, Liang Y, Sun Y. The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Metabolites. 2024;14(6):317. doi:10.3390/metabo14060317
BibTeX
@article{Zhou2024,
author = {Zhou, Qiqiang and Chen, Yahong and Liang, Ying and Sun, Yongchang},
title = {The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease},
journal = {Metabolites},
year = {2024},
volume = {14},
number = {6},
pages = {317},
doi = {10.3390/metabo14060317}
}
EUVIMED